XERS Q2 2019 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$320,000-60.9% YoY

Gross Profit

$297,00092.8% margin

Operating Income

-$34M-10643.8% margin

Net Income

-$34M-10745.3% margin

EPS (Diluted)

$-1.28

QoQ Revenue Growth

+29.0%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$134M

Total Liabilities

$59M

Stockholders' Equity

$75M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$320,000	$819,000	-60.9%
Gross Profit	$297,000	$819,000	-63.7%
Operating Income	-$34M	-$12M	-175.6%
Net Income	-$34M	-$13M	-164.8%